It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

Among some other larger deals, AbbVie acquired ImmunoGen last year ... see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy. Read why I’m maintaining ...

The North Chicago drugmaker could have a new foe — or frenemy — in a fellow Big Pharma firm trying to find wider uses for its ...

We recently compiled a list of the 14 Best 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

AbbVie delivered Y/Y growth in Q2 despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers. Read why I remain bullish on ABBV stock.

Morgan Stanley analyst Terence Flynn maintained a Buy rating on AbbVie (ABBV – Research Report) today and set a price target of $211.00. The company’s shares closed yesterday at $182.17.

AbbVie (ABBV) has recently been on ... there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Here at Zacks, we prioritize appraising the change in ...

In February, management completed the acquisition of ImmunoGen ... AbbVie currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Among some other larger deals, AbbVie acquired ImmunoGen last year, which added the latter’s ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest ...